UCLA Scientists Discover How Melanoma Resists Certain Treatment - Jan. 2015, Stand Up to Cancer
In a new study, funded in part by Stand Up To Cancer, led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage. Dr. Lo is a Stand Up To Cancer Innovative Research Grant (IRG) recipient. Dr. Ribas, a co-author of the study, is one of the team leaders of the SU2C-CRI Immunology Dream Team. Read more »
MRA-supported Investigators Announce Melanoma Breakthrough to Treating Drug Resistance - Jan. 2015, Cure Melanoma
UCLA researchers studying how people with melanoma build up resistances to treatment drugs have discovered signature genetic changes in tumors that give clues about how to counter the effect, the university reported Tuesday.
Researchers find clues on how melanoma resists effective treatments - Jan. 2015, Reuters
Researchers believe they have discovered a mechanism by which tumors eventually evade effective combination treatments for melanoma, providing clues that could lead to longer-lasting therapies for the deadliest of skin cancers. Read more »
Researchers reveal how melanoma becomes resistant to promising new drug combo therapy - Jan. 2015, News Medical
In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage. Read more »
UCLA Researchers Make Melanoma Discovery - Jan. 2015, Gilroy Patch
UCLA researchers studying how people with melanoma build up resistances to drugs used to fight it have discovered signature genetic changes in tumors that give clues about how to counter the effect, the university reported Tuesday. Read more »
Clues Found on How Melanoma Resists Treatments - Jan. 2015, Scientific American
Researchers believe they have discovered a mechanism by which tumors eventually evade effective combination treatments for melanoma, providing clues that could lead to longer-lasting therapies for the deadliest of skin cancers. Read more »
Study Reveals Mechanisms Behind Melanoma Combination Therapy Resistance - Jan. 2015, Melanoma News Today
Researchers from the UCLA Jonsson Comprehensive Cancer Center have published their latest results in the journal Cancer Cell, whereby they reveal how melanoma cells can become resistant to BRAF and MEK inhibitors after initial tumor regression.
Search unlocks how melanoma resists new drug combination therapy - Jan. 2015, Domain-B
Researchers at the UCLA Jonsson Comprehensive Cancer Center have uncovered how melanoma becomes resistant to a new drug combination therapy consisting of BRAF+MEK inhibitor - chemical compounds used to fight cancer. Read more »
UCLA researchers discover signature genetic changes in tumors - Jan. 2015, Westside Today
UCLA researchers studying how people with melanoma build up resistances to drugs used to fight it have discovered signature genetic changes in tumors that give clues about how to counter the effect, the university reported today. Read more »
Gifts - Oct. 2014, U Magazine
The Melanoma Research Alliance (MRA) has awarded a $900,000 Team Science Award to Dr. Roger Lo (RES '06), a member of the Jonsson Comprehensive Cancer Center with faculty appointments in the UCLA Department of Medicine, Division of Dermatology and the Department of Molecular and Medical Pharmacology; and his collaborator, Dr. Alain Algazi (MD '04, RES '05, '07) in the Division of Hematology/ Oncology at the University of California, San Francisco. Read more »
The U.S. Food and Drug Administration today approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated.
The drug, Keytruda, was tested on more than 600 patients who had melanoma that had spread throughout their bodies. Because so many of the patients in the early testing showed significant long-lasting responses, the study was continued and the FDA granted the drug “breakthrough therapy” status, allowing it to be fast-tracked for approval.
The largest Phase 1 study in the history of oncology, the research was conducted at UCLA and 11 other sites in the U.S., Europe and Australia.
